[Pubmed] Validation of the "Patient-Acceptable Symptom State" Question as Outcome Measure in AChR Myasthenia Gravis: A M
Posté : 25 juin 2025 12:00
Eur J Neurol. 2025 Jun;32(6):e70262. doi: 10.1111/ene.70262.
ABSTRACT
INTRODUCTION: Patient Acceptable Symptom State (PASS) is emerging as a valuable subjective measure of the overall myasthenia gravis (MG)-related burden. This study aimed at identifying PASS-positive thresholds for the most used clinical scales, investigating whether PASS and MGFA post-intervention status capture different aspects of the disease outcome, and identifying clinical variables associated with PASS=YES response.
METHODS: Adult AChR-MG patients were prospectively enrolled at two Italian Centres (Rome: index cohort; Florence: validation cohort). PASS thresholds for MG-ADL, QMG, and MG-QOL15r were defined in the index cohort by ROC analysis and validated in the validation cohort; predictors of favorable PASS were identified by multivariable analysis.
RESULTS: This study included 173 patients (44% females, median age at onset: 53 years). PASS=YES patients had significantly lower median MG-ADL, QMG, and MG-QOL15r scores, with the following thresholds for PASS=YES: MG ADL ≤ 2, QMG ≤ 8 and MG-QOL15r ≤ 6. The MG-ADL (OR = 0.46, 95% CI = 0.36-0.60, p < 0.001), QMG (OR = 0.72, 95% CI = 0.64-0.81, p < 0.001) and MG-QOL15r (OR = 0.76, 95% CI = 0.70-0.84, p < 0.001), were independently associated with a favorable PASS. The degree of ocular involvement in each scale was the strongest negative determinant of PASS=YES.
CONCLUSIONS: This study validates the PASS question and highlights the relevance of ocular complaints in patients' perception of MG burden.
PMID:40556475 | DOI:10.1111/ene.70262
Source: https://pubmed.ncbi.nlm.nih.gov/4055647 ... t9+e462414